CVOTs on DPP-4i Data from TECOS, EXAMINE, SAVOR-TIMI53, CARMELINA, and CAROLINA showed that DPP-4i are non-inferior to the placebo or glimepiride relative to primary cardiovascular endpoints [17, 48, 49, 57, 58]
[PMID: 8448982] PubMed record related to this compound for laboratory literature review
2fh) identifying GLP-1GIPLani as the lead candidate for subsequent studies
All of the addiction medicine specialists reported they had prescribed GLP-1RAs for weight loss, while 80 percent of gastroenterologists had done so, with other surveyed specialists ranging from 88 to 96 percent
143 (Pt 3), 113537
Evening application to both scalp and face is the most efficient protocol